These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 26293907

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis.
    Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, Trauner M.
    Liver Int; 2007 Sep; 27(7):920-9. PubMed ID: 17696930
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dysregulation of Circulating FGF19 and Bile Acids in Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome.
    Li Z, Liu Y, Yang F, Pang J, Wu Y, Chong Y, Li X.
    Biomed Res Int; 2020 Sep; 2020():1934541. PubMed ID: 32626734
    [Abstract] [Full Text] [Related]

  • 7. Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome.
    Johansson H, Svensson JF, Almström M, Van Hul N, Rudling M, Angelin B, Nowak G, Fischler B, Ellis E.
    J Intern Med; 2020 May; 287(5):534-545. PubMed ID: 31976601
    [Abstract] [Full Text] [Related]

  • 8. FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence.
    Simbrunner B, Hofer BS, Schwabl P, Zinober K, Petrenko O, Fuchs C, Semmler G, Marculescu R, Mandorfer M, Datz C, Trauner M, Reiberger T.
    Hepatol Int; 2024 Jun; 18(3):929-942. PubMed ID: 38332428
    [Abstract] [Full Text] [Related]

  • 9. Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.
    Zweers SJ, de Vries EM, Lenicek M, Tolenaars D, de Waart DR, Koelfat KV, Groen AK, Olde Damink SW, Beuers U, Ponsioen C, Jansen PL, Schaap FG.
    Hepatol Int; 2017 Jan; 11(1):132-140. PubMed ID: 27696157
    [Abstract] [Full Text] [Related]

  • 10. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man.
    Lundåsen T, Gälman C, Angelin B, Rudling M.
    J Intern Med; 2006 Dec; 260(6):530-6. PubMed ID: 17116003
    [Abstract] [Full Text] [Related]

  • 11. The Enterokine Fibroblast Growth Factor 15/19 in Bile Acid Metabolism.
    Cariello M, Piglionica M, Gadaleta RM, Moschetta A.
    Handb Exp Pharmacol; 2019 Dec; 256():73-93. PubMed ID: 31123830
    [Abstract] [Full Text] [Related]

  • 12. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis.
    Chen W, Wei Y, Xiong A, Li Y, Guan H, Wang Q, Miao Q, Bian Z, Xiao X, Lian M, Zhang J, Li B, Cao Q, Fan Z, Zhang W, Qiu D, Fang J, Gershwin ME, Yang L, Tang R, Ma X.
    Clin Rev Allergy Immunol; 2020 Feb; 58(1):25-38. PubMed ID: 30900136
    [Abstract] [Full Text] [Related]

  • 13. Dynamics of Bile Acid Profiles, GLP-1, and FGF19 After Laparoscopic Gastric Banding.
    Thöni V, Pfister A, Melmer A, Enrich B, Salzmann K, Kaser S, Lamina C, Ebenbichler CF, Hackl H, Tilg H, Moschen AR.
    J Clin Endocrinol Metab; 2017 Aug 01; 102(8):2974-2984. PubMed ID: 28591793
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impaired Hepatic Adaptation to Chronic Cholestasis induced by Primary Sclerosing Cholangitis.
    Milkiewicz M, Klak M, Kempinska-Podhorodecka A, Wiechowska-Kozlowska A, Urasinska E, Blatkiewicz M, Wunsch E, Elias E, Milkiewicz P.
    Sci Rep; 2016 Dec 23; 6():39573. PubMed ID: 28008998
    [Abstract] [Full Text] [Related]

  • 18. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.
    Zweers SJ, Booij KA, Komuta M, Roskams T, Gouma DJ, Jansen PL, Schaap FG.
    Hepatology; 2012 Feb 23; 55(2):575-83. PubMed ID: 21953282
    [Abstract] [Full Text] [Related]

  • 19. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
    Piglionica M, Cariello M, Moschetta A.
    Curr Opin Pharmacol; 2018 Dec 23; 43():93-98. PubMed ID: 30223181
    [Abstract] [Full Text] [Related]

  • 20. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
    Friedrich D, Marschall HU, Lammert F.
    BMC Gastroenterol; 2018 Jun 04; 18(1):76. PubMed ID: 29866129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.